Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

Elizabeth M.  Swisher

Stock and Other Ownership Interests  - IDEAYA Biosciences

Consulting or Advisory Role - IDEAYA Biosciences

Research Funding - Clovis Oncology; Tesaro

Rebecca Sophie  Kristeleit

Honoraria - AstraZeneca; Clovis Oncology; Merck Sharp & Dohme; Roche/Genentech; Tesaro

Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio

Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx

Amit M.  Oza

Honoraria - Intas

Consulting or Advisory Role - Immunogen; Merck KGaA

Research Funding - AstraZeneca (Inst); Immunovaccine (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Other Relationship - AstraZeneca; Clovis Oncology; Clovis Oncology; Merck; Tesaro

Anna  Tinker

Consulting or Advisory Role - AstraZeneca

Research Funding - AstraZeneca

Isabelle Laure  Ray-Coquard

Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genmab; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro

Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro

Research Funding - Bristol-Myers Squibb; MSD Oncology

Travel, Accommodations, Expenses - Advaxis; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro

(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA)

Ana  Oaknin

Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genmab; Immunogen; PharmaMar; Roche; Tesaro

Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Clovis Oncology (Inst); Eisai (Inst); Regeneron (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche

Robert L.  Coleman

Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro

Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech

Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group

Howard A.  Burris III

Employment - HCA Healthcare

Leadership - HCA Healthcare

Stock and Other Ownership Interests  - HCA Healthcare

Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)

Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis (Inst)

(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)

Carol  Aghajanian

Consulting or Advisory Role - Clovis Oncology; Eisai; Immunogen; Mersana; Roche; Tesaro

Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)

David M.  O'Malley

Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; AstraZeneca; Clovis Oncology; Eisai; Genelux; Genentech/Roche; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Leap Therapeutics; Marker Therapeutics; Novocure; OncoQuest; Tarveda Therapeutics; Tesaro; Translational Genomics Research Institute

Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Merck (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Tesaro (Inst); TRACON Pharma (Inst)

Alexandra  Leary

No Relationships to Disclose

Stephen  Welch

Honoraria - AstraZeneca; Ipsen; Roche Canada

Diane M.  Provencher

Leadership - AstraZeneca

Honoraria - AstraZeneca; Roche/Genentech

Consulting or Advisory Role - AstraZeneca

Travel, Accommodations, Expenses - Roche/Genentech

Geoffrey  Shapiro

Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology

Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)

Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17

Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology

Lee-may  Chen

Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Tesaro (Inst)

Ronnie  Shapira-Frommer

Honoraria - AstraZeneca; Bristol-Myers Squibb; medison; MSD Oncology; Neopharm; Novartis; Roche

Consulting or Advisory Role - Clovis Oncology; MSD Oncology; Vascular Biogenics

Sandra  Goble

Employment - Clovis Oncology

Stock and Other Ownership Interests  - Clovis Oncology

Lara  Maloney

Employment - Clovis Oncology

Stock and Other Ownership Interests  - Clovis Oncology

Kevin K.  Lin

Employment - Clovis Oncology

Stock and Other Ownership Interests  - Clovis Oncology

Travel, Accommodations, Expenses - Clovis Oncology

Iain A.  McNeish

Honoraria - Tesaro

Consulting or Advisory Role - AstraZeneca; Carrick Therapeutics; Clovis Oncology; Takeda; Tesaro

Research Funding - AstraZeneca (Inst)

Travel, Accommodations, Expenses - AstraZeneca